J.A. Lockton

586 citations

14 papers · 458 indexed · h-index 11

Impact in

Pharmacology top 10%
- Pharmacogenetics and Drug Metabolism
Endocrinology, Diabetes and Metabolism top 10%
- Diabetes, Cardiovascular Risks, and Lipoproteins

Papers in ⓘ

Public Health, Environmental and Occupational Health 4
- Nutritional Studies and Diet 2
- Obesity, Physical Activity, Diet 2
Endocrinology, Diabetes and Metabolism 4
- Diabetes, Cardiovascular Risks, and Lipoproteins 2
- Diet, Metabolism, and Disease 1

Co-authors: Glen Clack (2 shared papers)Richard Eastell (1 shared paper)Richard D. Finkelman (1 shared paper)R.A. Hannon (1 shared paper)Alan Swaisland (1 shared paper)E. E. M. Kernohan (2 shared papers)Andrea Bedford (2 shared papers)Puneet Sahota (2 shared papers)
Journals: Diabetic Medicine (2 papers)British Journal of Clinical Pharmacology (2 papers)Psychopharmacology (1 paper)Journal of Clinical Oncology (1 paper)Heart (1 paper)
Partner nations: United Kingdom Sweden Australia

In The Last Decade

J.A. Lockton

14 papers receiving 441 citations

Peers

Replace Chung‐Yu Huang with:

Chung‐Yu Huang Taiwan

Ching‐Chu Chen Taiwan

Yamato Kato Japan

Pipasha Biswas United Kingdom

Evgeny Krynetskiy United States

Xia Zhang China

Natsumi Ueda Japan

Lucjan Pawlicki Poland

Chrysoula Boutari Greece

J. Zimmerman Israel

J.A. Lockton relative to Chung‐Yu Huang Taiwan Chung‐Yu Huang's profile →

Citations per field

00.5×1.5×2×2.4×

Chung‐Yu Huang · 1×

×2.4 57/24

PHARM

×2.1 104/50

EDM

×1.7 108/65

ONCOL

×0.5 90/193

PHYSI

×2.1 25/12

OSM

Citations per year

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Countries citing papers authored by J.A. Lockton

Since Specialization

Citations

This map shows the geographic impact of J.A. Lockton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.A. Lockton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.A. Lockton more than expected).

Fields of papers citing papers by J.A. Lockton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.A. Lockton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.A. Lockton. The network helps show where J.A. Lockton may publish in the future.

Co-authors

The 25 scholars most cited alongside J.A. Lockton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J.A. Lockton Line = papers co-authored together J.A. Lockton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work
1	Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial Journal of Bone and Mineral Research ·R.A. Hannon, Glen Clack, Martin Rimmer, Alan Swaisland, J.A. Lockton, Richard D. Finkelman, Richard Eastell	2009	89
2	Insulin resistance, diabetes, and risk markers for ischaemic heart disease in Asian men and non-Asian in Bradford. Heart ·Taylor Knight, Z. Smith, A Whittles, Puneet Sahota, J.A. Lockton, Georgina R. Hogg, Andrea Bedford, M Toop, E. E. M. Kernohan, Mark Baker	1992	76
3	Pharmacokinetic and pharmacodynamic assessment of a five‐probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1 British Journal of Clinical Pharmacology ·Graham Blakey, J.A. Lockton, John Perrett, Paul Norwood, Muir Russell, Z. Aherne, J. Plume	2003	58
4	Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index Metabolism ·Toralph Ruge, J.A. Lockton, Frida Renström, Ted Lystig, Valentina Sukonina, Maria Svensson, Jan W. Eriksson	2009	57
5	Diabetic Diets and Nutritional Recommendations: What Happens in Real Life? Diabetic Medicine ·E.J. Close, Philip Wiles, J.A. Lockton, D. Walmsley, J. Oldham, J K Wales	1992	33
6	A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic Psychopharmacology ·Johannes G. Ramaekers, C. Lamers, Frans R.J. Verhey, N. D. Muntjewerff, E.J. Mobbs, N. Sanders, Lewis Jw, J.A. Lockton	2001	28
7	Ethnic differences in risk markers for heart disease in Bradford and implications for preventive strategies. Journal of Epidemiology & Community Health ·Taylor Knight, Z. Smith, J.A. Lockton, Puneet Sahota, Andrea Bedford, M Toop, E. E. M. Kernohan, Mark Baker	1993	25
8	Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor Journal of Clinical Oncology ·J.A. Lockton, Dominic Smethurst, M. Macpherson, R. Tootell, A. Marshall, Glen Clack, Neil J. Gallagher	2005	22
9	A retrospective study of thirty-two patients with small-cell bronchogenic carcinoma and inappropriate secretion of antidiuretic hormone Clinical Radiology ·J.A. Lockton, N. Thatcher	1986	18
10	The Degree of Day‐to‐day Variation in Food Intake in Diabetic Patients Diabetic Medicine ·E.J. Close, Philip Wiles, J.A. Lockton, D. Walmsley, J. Oldham, J K Wales	1993	17
11	Variability in fasting lipid and glycogen contents in hepatic and skeletal muscle tissue in subjects with and without type 2 diabetes: a ¹H and ¹³C MRS study NMR in Biomedicine ·Mary C. Stephenson, E. Leverton, Eric Yin Hao Khoo, Simon M. Poucher, Lars Johansson, J.A. Lockton, Jan W. Eriksson, Peter Mansell, Peter G. Morris, Ian Macdonald	2013	17
12	Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis Journal of Pharmacological and Toxicological Methods ·J.A. Lockton, Simon M. Poucher	2006	10
13	Fatal Pasteurella multocida septicaemia following a cat bite in a man without liver disease Journal of Infection ·AM Jones, J.A. Lockton	1987	7
14	Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males British Journal of Clinical Pharmacology ·W. D. Hooper, Mervyn J. Eadie, Graham Blakey, J.A. Lockton, M. Manun'Ebo	2001	1

About J.A. Lockton

J.A. Lockton is a scholar working on Public Health, Environmental and Occupational Health, Endocrinology, Diabetes and Metabolism, Physiology, Molecular Biology and Epidemiology, having authored 14 papers that have together received 458 indexed citations. Recurring topics across this work include Diet and metabolism studies (3 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers), Nutritional Studies and Diet (2 papers), Obesity, Physical Activity, Diet (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Pancreatic function and diabetes (1 paper), Diet, Metabolism, and Disease (1 paper) and Pharmacological Effects and Toxicity Studies (1 paper). The work is most often cited by research in Pharmacology (57 citations), Endocrinology, Diabetes and Metabolism (104 citations), Oncology (108 citations), Physiology (90 citations) and Orthopedics and Sports Medicine (25 citations). J.A. Lockton has collaborated with scholars based in United Kingdom, Sweden and Australia. Frequent co-authors include Glen Clack, Richard Eastell, Richard D. Finkelman, R.A. Hannon, Alan Swaisland, E. E. M. Kernohan, Andrea Bedford, Puneet Sahota, Mark Baker and Jan W. Eriksson. Their work appears in journals such as Diabetic Medicine, British Journal of Clinical Pharmacology, Psychopharmacology, Journal of Clinical Oncology and Heart.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact